Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy

Journal of Molecular Endocrinology

Volumn 59, Issue 1, 2017, Pages R1-R10

  Hasan, Ahmed A ^a,b   Hocher, Berthold ^a,c,d  

^a UNIVERSITY OF POTSDAM   (Germany)

^b Zagazig University   (Egypt)

^c Institut für Laboriatorumsmedizin IFLb   (Germany)

^d JINAN UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; DPP 4; DPP 4 inhibitors; GLP 1 and SDF 1a

Indexed keywords

ALOGLIPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GEMIGLIPTIN; GLUCAGON LIKE PEPTIDE 1; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; STREPTOZOCIN; STROMAL CELL DERIVED FACTOR 1ALPHA; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT; CXCL12 PROTEIN, HUMAN; DPP4 PROTEIN, HUMAN; PROTECTIVE AGENT; STROMAL CELL DERIVED FACTOR 1;

ALBUMINURIA; ANTIDIABETIC ACTIVITY; CELL MEMBRANE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG EFFICACY; DRUG HALF LIFE; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; HUMAN; KIDNEY; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VOLUME OF DISTRIBUTION; AGONISTS; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MESANGIUM CELL; METABOLISM; PATHOLOGY; PODOCYTE; PRECLINICAL STUDY;

ANIMALS; CHEMOKINE CXCL12; CLINICAL TRIALS AS TOPIC; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MESANGIAL CELLS; PODOCYTES; PROTECTIVE AGENTS;

EID: 85024907511     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-17-0005     Document Type: Review

References (60)

1. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Klein T & Hocher B 2012 DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney and Blood Pressure Research 36 119–130. (doi:10.1159/000341487)
2. Chaykovska L, Alter ML, von Websky K, Hohmann M, Tsuprykov O, Reichetzeder C, Kutil B, Kraft R, Klein T & Hocher B 2013 Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. Journal of Hypertension 31 2290–2298; discussion 2299. (doi:10.1097/HJH.0b013e3283649b4d)
3. Cooper ME, Perkovic V, Groop PH, Hocher B, Cescutti J, Meinicke T, KoitkaWeber A, Thiemann S & von Eynatten M 2016 Abstracts of 52nd EASD annual meeting. Diabetologia 59 (Supplement 1) 1–581. (doi:10.1007/s00125-016-4046-9)
4. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G & Girardi AC 2011 Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. American Journal of Physiology: Renal Physiology 301 F355–F363. (doi:10.1152/ajprenal.00729.2010)
5. Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, et al. 2014a The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney International 85 579–589. (doi:10.1038/ki.2013.427)
6. Fujita H, Taniai H, Murayama H, Ohshiro H, Hayashi H, Sato S, Kikuchi N, Komatsu T, Komatsu K, Narita T, et al. 2014b DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathy. Endocrine Journal 61 159–166. (doi:10.1507/endocrj.EJ13-0305)
7. Goldshtein I, Karasik A, Melzer-Cohen C, Engel SS, Yu S, Sharon O, Brodovicz K, Gadir N, Katzeff HL, Radican L, et al. 2016 Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: a real-world evidence study. Journal of Diabetic Complications 30 1354–1359. (doi:10.1016/j.jdiacomp.2016.05.012)
8. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ & von Eynatten M 2013 Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36 3460–3468. (doi:10.2337/dc13-0323)
9. Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, et al. 2015 Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D trial. Diabetes and Vascular Disease Research 12 455–462. (doi:10.1177/1479164115579002)
10. Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, et al. 2016 Abstracts of 52nd EASD annual meeting. Diabetologia 59 (Supplement 1) 1–581. (doi:10.1007/s00125-016-4014-4)
11. Hartel S, Gossrau R, Hanski C & Reutter W 1988 Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 89 151–161. (doi:10.1007/BF00489918)
12. Hattori S 2011 Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocrine Journal 58 69–73. (doi:10.1507/endocrj.K10E-382)
13. Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, Yokomizo H, Hirata E, Sonoda N & Takayanagi R 2012 GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 61 1422–1434. (doi:10.1016/j. metabol.2012.03.002)
14. Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S & Nangaku M 2015 Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. American Journal of Physiology: Renal Physiology 308 F878–F887. (doi:10.1152/ajprenal.00590.2014)
15. Hopsu-Havu VK & Glenner GG 1966 A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 7 197–201. (doi:10.1007/BF00577838)
16. Imamura S, Hirai K & Hirai A 2013 The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku Journal of Experimental Medicine 231 57–61. (doi:10.1620/tjem.231.57)
17. Ingelfinger JR & Rosen CJ 2016 Cardiac and renovascular complications in type 2 diabetes – is there hope? New England Journal of Medicine 375 380–382. (doi:10.1056/NEJMe1607413)
18. Jackson EK, Kochanek SJ & Gillespie DG 2012 Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension 60 757–764. (doi:10.1161/HYPERTENSIONAHA.112.196501)
19. Jung E, Kim J, Ho Kim S, Kim S & Cho MH 2015 Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy. European Journal of Pharmacology 761 116–124. (doi:10.1016/j.ejphar.2015.04.055)
20. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, Ishigaki Y, Kitada M, Srivastava SP & Koya D 2014 Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63 2120–2131. (doi:10.2337/db13-1029)
21. Kettmann U, Humbel B & Holzhausen HJ 1992 Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. Acta Histochemica 92 225–227. (doi:10.1016/S0065-1281(11)80085-1)
22. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, et al. 2011 Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54 965–978. (doi:10.1007/s00125-010-2028-x)
23. Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK & Makino H 2014 Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochemical and Biophysical Research Communications 443 828–833. (doi:10.1016/j.bbrc.2013.12.049)
24. Li W, Cui M, Wei Y, Kong X, Tang L & Xu D 2012 Inhibition of the expression of TGF-beta1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cellular Physiology and Biochemistry 30 749–757. (doi:10.1159/000341454)
25. Lim SW, Jin L, Piao SG, Chung BH & Yang CW 2015 Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury. Laboratory Investigation 95 1174–1185. (doi:10.1038/labinvest.2015.93)
26. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM & Park TS 2012 Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. Journal of Pharmacology and Experimental Therapeutics 340 248–255. (doi:10.1124/jpet.111.186866)
27. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. 2016 Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 375 311–322. (doi:10.1056/NEJMoa1603827)
28. Matsui T, Nakashima S, Nishino Y, Ojima A, Nakamura N, Arima K, Fukami K, Okuda S & Yamagishi S 2015 Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Laboratory Investigation 95 525–533. (doi:10.1038/labinvest.2015.35)
29. Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F & Reis F 2011 Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experimental Diabetes Research 2011 162092. (doi:10.1155/2011/162092)
30. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, Matsumoto M, Mizutani K, Park K, Cahill C, et al. 2012 Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 61 2967–2979. (doi:10.2337/db11-1824)
31. Min HS, Kim JE, Lee MH, Song HK, Kang YS, Lee MJ, Lee JE, Kim HW, Cha JJ, Chung YY, et al. 2014 Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Laboratory Investigation 94 598–607. (doi:10.1038/labinvest.2014.50)
32. Mitic B, Lazarevic G, Vlahovic P, Rajic M & Stefanovic V 2008 Diagnostic value of the aminopeptidase N,N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Renal Failure 30 896–903. (doi:10.1080/08860220802359048)
33. Moon JY, Woo JS, Seo JW, Lee A, Kim DJ, Kim YG, Kim SY, Lee KH, Lim SJ, Cheng XW, et al. 2016 The dose-dependent organ-specific effects of a dipeptidyl peptidase-4 inhibitor on cardiovascular complications in a model of type 2 diabetes. PLoS ONE 11 e0150745. (doi:10.1371/journal.pone.0150745)
34. Mulvihill EE & Drucker DJ 2014 Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocrine Reviews 35 992–1019. (doi:10.1210/er.2014-1035)
35. Nakashima S, Matsui T, Takeuchi M & Yamagishi SI 2014 Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Hormone and Metabolic Research 46 717–721. (doi:10.1055/s-0034-1371892)
36. Nistala R, Habibi J, Aroor A, Sowers JR, Hayden MR, Meuth A, Knight W, Hancock T, Klein T, DeMarco VG, et al. 2014 DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity 22 2172–2179. (doi:10.1002/oby.20833)
37. Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K & Yamagishi S 2013 Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. American Journal of Pathology 182 132–141. (doi:10.1016/j.ajpath.2012.09.016)
38. Panchapakesan U & Pollock CA 2014 DPP-4 inhibitors-renoprotection in diabetic nephropathy? Diabetes 63 1829–1830. (doi:10.2337/db14-0366)
39. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, et al. 2007 Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. Journal of the American Society of Nephrology 18 1227–1238. (doi:10.1681/ASN.2006070778)
40. Pyke C & Knudsen LB 2013 The glucagon-like peptide-1 receptor – or not? Endocrinology 154 4–8. (doi:10.1210/en.2012-2124)
41. Reichetzeder C, von Websky K, Tsuprykov O, Mohagheghi Samarin A, Falke LG, Dwi Putra SE, Hasan AA, Antonenko V, Curato C& Rippman J, et al. 2017 Head to head comparison of structurally unrelated DPP4 inhibitors in the setting of renal ischemia reperfusion injury. British Journal of Pharmacology [in press]. (doi:10.1111/bph.13822)
42. Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, Drucker DJ & Vallon V 2012 Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. American Journal of Physiology: Renal Physiology 303 F963–F971. (doi:10.1152/ajpcell.00217.2012)
43. Sakata K, Hayakawa M, Yano Y, Tamaki N, Yokota N, Eto T, Watanabe R, Hirayama N, Matsuo T, Kuroki K, et al. 2013 Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes/ Metabolism Research and Reviews 29 624–630. (doi:10.1002/dmrr.2437)
44. Sayyed SG, Hagele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S & Anders HJ 2009 Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52 2445–2454. (doi:10.1007/s00125-009-1493-6)
45. Schlatter P, Beglinger C, Drewe J & Gutmann H 2007 Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regulatory Peptides 141 120–128. (doi:10.1016/j. regpep.2006.12.016)
46. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. 2013 Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine 369 1317–1326. (doi:10.1056/NEJMoa1307684)
47. Sharkovska Y, Reichetzeder C, Alter M, Tsuprykov O, Bachmann S, Secher T, Klein T & Hocher B 2014 Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. Journal of Hypertension 32 2211–2223; discussion 2223. (doi:10.1097/HJH.0000000000000328)
48. Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, Nitta K, Takagi S, Kanasaki K & Koya D 2015 Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney International 88 479–489. (doi:10.1038/ki.2015.103)
49. Stange T, Kettmann U & Holzhausen HJ 1996 Immunoelectron microscopic single and double labelling of aminopeptidase N (CD 13) and dipeptidyl peptidase IV (CD 26). Acta Histochemica 98 323–331. (doi:10.1016/S0065-1281(96)80025-0)
50. Takashima S, Fujita H, Fujishima H, Shimizu T, Sato T, Morii T, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, et al. 2016 Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney International 90 783–796. (doi:10.1016/j.kint.2016.06.012)
51. Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenfuhrer J, Hasan AA, Tammen H, et al. 2016 The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney International 89 1049–1061. (doi:10.1016/j.kint.2016.01.016)
52. Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD & Botros FT 2016 Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes, Obesity and Metabolism 19 436–441. (doi:10.1111/dom.12816)
53. Ulmer AJ, Mattern T, Feller AC, Heymann E & Flad HD 1990 CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19–4-7 and 4EL1C7. Scandinavian Journal of Immunology 31 429–435. (doi:10.1111/j.1365-3083.1990.tb02789.x)
54. Vivier I, Marguet D, Naquet P, Bonicel J, Black D, Li CX, Bernard AM, Gorvel JP & Pierres M 1991 Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). Journal of Immunology 147 447–454.
55. von Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen TW & Rossing P 2016 The effect of liraglutide on renal function: a randomized clinical trial. Diabetes, Obesity and Metabolism 19 239–247. (doi:10.1111/dom.12808)
56. von Websky K, Reichetzeder C & Hocher B 2014 Physiology and pathophysiology of incretins in the kidney. Current Opinion in Nephrology and Hypertension 23 54–60. (doi:10.1097/01. mnh.0000437542.77175.a0)
57. Wang Z, Grigo C, Steinbeck J, von Horsten S, Amann K & Daniel C 2014 Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides 57 109–117. (doi:10.1016/j. peptides.2014.05.006)
58. Yang J, Campitelli J, Hu G, Lin Y, Luo J & Xue C 2007 Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Science 81 272–279. (doi:10.1016/j. lfs.2007.04.040)
59. Yin QH, Zhang R, Li L, Wang YT, Liu JP, Zhang J, Bai L, Cheng JQ, Fu P & Liu F 2016 Exendin-4 ameliorates lipotoxicity-induced glomerular endothelial cell injury by improving ABC transporter A1-mediated cholesterol efflux in diabetic apoE knockout mice. Journal of Biological Chemistry 291 26487–26501. (doi:10.1074/jbc.M116.730564)
60. Zeisberg M & Zeisberg EM 2015 Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney International 88 429–431. (doi:10.1038/ki.2015.175)